Do beta‑blockers affect the QT interval?

Beta-Blockers and QT Interval Effects

Beta-blockers do not prolong the QT interval in most clinical contexts and are actually the first-line therapy for long QT syndrome (LQTS), where they reduce life-threatening arrhythmias despite having minimal effect on resting QTc. However, one specific beta-blocker—sotalol—is a notable exception that significantly prolongs the QT interval and carries risk for torsades de pointes 1.

Context-Dependent Effects on QT Interval

Standard Beta-Blockers (Propranolol, Atenolol, Nadolol, Metoprolol)

These agents demonstrate heart-rate-dependent effects on QT dynamics rather than causing problematic QT prolongation 2:

• At slower heart rates (<90 bpm), beta-blockers may slightly increase both QT and QTc intervals (QT: 405 vs 409 ms; QTc: 459 vs 464 ms) 2
• At faster heart rates (>100 bpm), beta-blockers actually shorten both QT and QTc intervals (QT: 367 vs 358 ms, p<0.0001; QTc: 500 vs 486 ms, p<0.0001) 2
• The QT interval shortens faster with increasing heart rate in patients on beta-blockers compared to those not using them, which may explain their protective effect against exercise-induced ventricular arrhythmias 3

Genotype-Specific Effects in Long QT Syndrome

The effect of beta-blockers on QTc duration differs significantly by LQTS genotype 4:

• In LQT1 patients: Beta-blockers prolong QT1000 interval (from 481±39 to 498±43 ms, p<0.01) 4
• In LQT2 patients: Beta-blockers shorten QT1000 interval (from 521±38 to 503±32 ms, p<0.01) 4
• Despite these differential effects on QTc, beta-blockers reduce adverse cardiac events by >95% in LQT1, >75% in LQT2, and >60% in females with LQT3 1

Sotalol: The Exception

Sotalol is fundamentally different from other beta-blockers because it has substantial Class III antiarrhythmic activity that causes QT prolongation and carries risk for torsades de pointes 1:

• Sotalol prolongs the QT interval through potassium channel blockade (IKr inhibition) 1
• The drug carries precautions for prolonged QT, renal dysfunction, hypokalemia, and requires QT monitoring 2-4 hours after each dose 1
• If QT interval prolongs to ≥500 ms during sotalol therapy, the dose must be reduced or discontinued 1
• Sotalol can cause life-threatening torsades de pointes, particularly in patients with impaired kidney function 1

Mechanism of Protection in LQTS

Beta-blockers protect LQTS patients primarily by reducing dispersion of repolarization and preventing early afterdepolarizations, not by shortening the QT interval 5, 6:

• Beta-blockers markedly reduce the T-peak-to-end interval (Tpe), an electrocardiographic marker of transmural dispersion of repolarization, during exercise (91±26 ms vs 67±19 ms, p=0.03) and recovery (103±26 ms vs 78±11 ms, p=0.02) 6
• They decrease the T2/T1 amplitude ratio (from 3.0±1.0 to 2.2±0.6, p=0.002), which reflects prevention of early afterdepolarizations 5
• These effects are most pronounced at elevated heart rates, explaining why beta-blockers prevent exercise-induced cardiac events in LQTS 5

Clinical Recommendations

For patients with LQTS and QTc ≥470 ms, beta-blockers are Class I recommended therapy 1:

• Nadolol shows superior efficacy in LQT2 and is effective in both LQT1 and LQT2 1, 7
• Propranolol and atenolol are effective in LQT1 1, 7
• Metoprolol appears less effective across genotypes 1, 7
• Patients receiving beta-blockers require ongoing monitoring to assess QTc changes over time and adequacy of beta-blockade with exertion 1

QT-prolonging medications (including sotalol) are potentially harmful in patients with LQTS and should be avoided 1.

Common Pitfall

Do not confuse standard beta-blockers with sotalol. While propranolol, atenolol, nadolol, and metoprolol do not cause clinically significant QT prolongation and are protective in LQTS, sotalol is a hybrid beta-blocker/Class III antiarrhythmic that definitively prolongs QT and requires careful monitoring for proarrhythmia 1.